AADI vs. RMTI, IMRX, BOLT, CLNN, JAN, APLM, OCUP, MRKR, NXTC, and XLO
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Rockwell Medical (RMTI), Immuneering (IMRX), Bolt Biotherapeutics (BOLT), Clene (CLNN), JanOne (JAN), Apollomics (APLM), Ocuphire Pharma (OCUP), Marker Therapeutics (MRKR), NextCure (NXTC), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Aadi Bioscience (NASDAQ:AADI) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are owned by institutional investors. 35.8% of Aadi Bioscience shares are owned by company insiders. Comparatively, 1.9% of Rockwell Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Aadi Bioscience had 4 more articles in the media than Rockwell Medical. MarketBeat recorded 5 mentions for Aadi Bioscience and 1 mentions for Rockwell Medical. Aadi Bioscience's average media sentiment score of 0.10 beat Rockwell Medical's score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the media.
Aadi Bioscience has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Rockwell Medical received 290 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 57.33% of users gave Rockwell Medical an outperform vote while only 50.00% of users gave Aadi Bioscience an outperform vote.
Rockwell Medical has higher revenue and earnings than Aadi Bioscience. Rockwell Medical is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Aadi Bioscience currently has a consensus target price of $24.67, suggesting a potential upside of 1,158.50%. Rockwell Medical has a consensus target price of $7.00, suggesting a potential upside of 324.24%. Given Aadi Bioscience's higher possible upside, research analysts plainly believe Aadi Bioscience is more favorable than Rockwell Medical.
Rockwell Medical has a net margin of -10.09% compared to Aadi Bioscience's net margin of -270.04%. Rockwell Medical's return on equity of -39.17% beat Aadi Bioscience's return on equity.
Summary
Rockwell Medical beats Aadi Bioscience on 11 of the 18 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
